Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Outcomes of sphincterotomy for small pupil phacoemulsification

Poster Details

First Author: J.Goh UK

Co Author(s):    R. Harrison   S. Tavassoli   D. Tole              

Abstract Details

Purpose:

Sphincterotomy, an alternative to iris hooks or pupil stretching, is a technique that can aid in small pupil phacoemulsification. The safety of this procedure, however, is currently unknown. This study evaluates the post-operative outcomes of phacoemulsification surgery with adjunctive pupillary sphincterotomy.

Setting:

Bristol Eye Hospital, United Kingdom

Methods:

A retrospective review of case notes of patients that had undergone simultaneous sphincterotomy, phacoemulsification and intraocular lens (IOL) implantation by a single surgeon between March 2012 and Feb 2017. Main outcome measures were post-operative intraocular pressure (IOP) rise (>21mmHg), uveitis and cystoid macular oedema (CMO).

Results:

125 eyes of 120 patients were included in this study. The mean age was 81 years (range: 26-100). All had uncomplicated surgery. 7 (5.6%) eyes developed a transient IOP rise at a mean follow-up of 14 days, of which 2 eyes had glaucoma and 3 were on an alpha-blocker. 3 (2.4%) eyes had persistent uveitis (>1 month) which resolved with topical therapy except for one eye with a history of uveitis. The 6 (4.8%) eyes that developed CMO had a history significant for uveitis (n=4), diabetic macular oedema (n=1) and epiretinal membrane (n=1). All CMO maculae resolved to their baseline.

Conclusions:

The incidence of post-operative complications following uncomplicated phacoemulsification and IOL implantation with pupillary sphincterotomy is low. The most important predisposing factors for development of a complication are ocular co-morbidities such as uveitis, glaucoma and the presence of a macular pathology.

Financial Disclosure:

NONE

Back to Poster listing